Hematologic Oncology | Specialty

Success of First BTK Inhibitor Opens New Options in B-Cell Malignancies

March 3rd 2014

A greater understanding of the molecular mechanisms underlying lymphoid malignancies has fostered the development of targeted therapies, including those aimed at B-cell signaling pathways.

Dr. Melnick on Epigenetic Diversity in DLBCL

March 3rd 2014

Ari Melnick, MD, professor of medicine, Weill Cornell Medical College, discusses the association between epigenetic diversity and clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL).

Dr. Goy on the Challenges of Treating Hodgkin's Lymphoma

February 27th 2014

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the challenges of treating patients with Hodgkin's lymphoma.

Idelalisib Shows Promising Activity in Heavily Pretreated iNHL

February 26th 2014

Treatment with the oral PI3K-delta inhibitor idelalisib produced an overall response rate of 57% with an average response duration of 12.5 months in heavily pretreated patients with indolent non-Hodgkin's lymphoma.

Dr. Erba on BCR-ABL Ratio After Imatinib in CML

February 25th 2014

Harry Erba, MD, PhD, discusses the frequency in which patients with chronic-phase chronic myeloid leukemia (CML) fail to achieve a BCR-ABL transcript level below 10% after 3 months of treatment with imatinib.

Rare Type of Leukemia Responds to Melanoma Treatment Vemurafenib

February 20th 2014

Vemurafenib (Zelboraf), a BRAF inhibitor approved to treat melanoma, induced a complete clinical remission in a patient with hairy cell leukemia.

Dr. Litzow on MRD Assessment in ALL

February 19th 2014

Mark R. Litzow. MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses ways of conducting minimal residual disease (MRD) assessments in patients with acute lymphoblastic leukemia

Dr. Phillips Discusses the Treatment of ATLL

February 11th 2014

Adrienne Phillips, MD, MPH, assistant professor of clinical medicine, Columbia University Medical Center, discusses advances in the treatment of HTLV-related adult T-cell leukemia lymphoma.

Six Targeted Agents for CLL Command Spotlight at ASH

February 10th 2014

A crop of targeted agents have demonstrated promising results in fighting chronic lymphocytic leukemia (CLL), suggesting that a range of emerging therapies and drug combinations may be more effective and better tolerated than standard chemotherapy

Sawyers' Scientific Approach Paved Way for Discoveries in Two Tumor Types

February 10th 2014

During his undergraduate years at Princeton University, Charles L. Sawyers, MD, studied history. Now, well into his career as a physician and translational scientist, Sawyers is busy making it.

Dr. Brentjens on CD19-Targeted T Cells in Leukemia

February 7th 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-targeted T Cells.

FDA Grants Belinostat Priority Review for Advanced PTCL

February 6th 2014

The FDA has granted a priority review designation to the intravenous pan-HDAC inhibitor belinostat (Beleodaq) as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma

Genmab Focuses Oncology Research on Monoclonal Antibodies

February 6th 2014

Genmab, the publicly traded, international biotechnology company, has an oncology pipeline that focuses on two classes of drugs: naked antibodies and antibody drug conjugates

Dr. Levis on the Ideal Use of Quizartinib in FLT3-ITD AML

February 5th 2014

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

Brentuximab Vedotin Studies Explore Novel Combinations, Pretransplant Settings

January 30th 2014

Alison J. Moskowitz, MD, is among researchers at Memorial Sloan-Kettering Cancer Center and elsewhere who are investigating an expanded role for the CD30-targeting brentuximab vedotin (Adcetris) in hematologic malignancies. Moskowitz specializes in the treatment of patients with lymphoma and her research focuses on evaluating novel treatments for Hodgkin lymphoma.

Changing Therapeutic Landscape in ALL, CLL, and NHL

January 22nd 2014

Combination Therapy in Large Cell Lymphomas

January 22nd 2014

Brentuximab Vedotin in Diffuse Large B-cell Lymphoma

January 22nd 2014

PI3K Inhibition in Hematologic Malignancies

January 22nd 2014

Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas

January 22nd 2014